Enovis (NYSE:ENOV) Hits New 52-Week Low - What's Next?

Key Points

• Enovis shares hit a new 52-week low, trading as low as $17.30 and closing around $17.92, well below the 50-day and 200-day moving averages near $25.
• Despite the selloff, analysts maintain a broadly positive outlook: 10 analysts rate the stock Buy, with a consensus “Moderate Buy” rating and an average price target of $40.38.
• The company exceeded quarterly earnings and revenue expectations, while insiders purchased about $449,600 of shares over the past three months, signaling confidence amid the decline.

Enovis Corporation (NYSE:ENOV - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $17.30 and last traded at $17.9220, with a volume of 2658431 shares changing hands. The stock had previously closed at $18.22.

Analysts Set New Price Targets

ENOV has been the topic of several research reports. UBS Group reaffirmed a "buy" rating and issued a $51.00 target price (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. Zacks Research raised Enovis from a "strong sell" rating to a "hold" rating in a report on Wednesday, July 29th. Wall Street Zen upgraded Enovis from a "hold" rating to a "buy" rating in a research note on Saturday. Citizens Jmp decreased their price objective on Enovis from $55.00 to $47.00 and set a "market outperform" rating on the stock in a report on Wednesday, September 2nd. Finally, Canaccord Genuity Group lowered their price target on shares of Enovis from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Monday, August 17th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $40.38.

Enovis Stock Performance

The firm has a market cap of $1.03 billion, a P/E ratio of -0.93 and a beta of 1.31. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98. The company's 50 day moving average is $24.95 and its 200 day moving average is $24.04.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The company had revenue of $582.78 million for the quarter, compared to analysts' expectations of $581.84 million. During the same period in the previous year, the business posted $0.79 earnings per share. The business's quarterly revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities analysts predict that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Enovis news, CEO Damien Mcdonald acquired 13,035 shares of the stock in a transaction dated Friday, September 4th. The stock was purchased at an average cost of $19.15 per share, with a total value of $249,620.25. Following the transaction, the chief executive officer owned 247,077 shares in the company, valued at approximately $4,731,524.55. The trade was a 5.57% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Oliver Engert bought 5,140 shares of the stock in a transaction on Thursday, September 3rd. The stock was acquired at an average price of $19.46 per share, with a total value of $100,024.40. Following the completion of the acquisition, the insider owned 61,238 shares of the company's stock, valued at $1,191,691.48. This represents a 9.16% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 23,293 shares of company stock valued at $449,599 in the last three months. 2.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ENOV. Paradigm Capital Management Inc. NY grew its holdings in Enovis by 70.2% in the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company's stock worth $40,420,000 after purchasing an additional 732,917 shares during the period. River Road Asset Management LLC boosted its position in shares of Enovis by 3.2% during the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company's stock worth $39,621,000 after purchasing an additional 46,289 shares in the last quarter. Private Management Group Inc. boosted its position in shares of Enovis by 38.8% during the 2nd quarter. Private Management Group Inc. now owns 1,365,082 shares of the company's stock worth $28,257,000 after purchasing an additional 381,705 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Enovis by 38.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company's stock valued at $24,430,000 after buying an additional 287,687 shares during the period. Finally, Royce & Associates LP raised its stake in Enovis by 14.6% during the 4th quarter. Royce & Associates LP now owns 826,848 shares of the company's stock worth $22,027,000 after buying an additional 105,608 shares during the period. 98.45% of the stock is owned by institutional investors.

About Enovis

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient mobility, support recovery and restore physical function. Its offerings serve orthopedic, sports medicine, rehabilitation and pain-management markets, with products used by healthcare professionals, athletes and patients.

The company's product portfolio includes orthopedic braces and supports, surgical solutions, cold and compression therapy systems, rehabilitation equipment, physical therapy devices and recovery technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.